SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET). The presentation will be available through a live webcast and archived at investor.myriad.com. About Myriad Genetics Myriad Genetics is a leading molecular diagnostic testin ...

Core Insights - Biomerica, Inc. has received authorization from the Egyptian Drug Authority for its complete portfolio of rapid diagnostic tests, enhancing access to early detection tools for cancer and chronic diseases in Egypt [1][2][10] Product Portfolio - The authorized screening tests include those for colorectal disease, breast self-examination, prostate disease, kidney disease, and H. pylori infection, all designed for point-of-care use [1][3][7] - Tests provide quick results within minutes and do not require laboratory sample processing, making them suitable for diverse clinical and community settings [3][14] Market Need - Colorectal cancer is the 7th most common cancer in Egypt, with an incidence of approximately 5 to 10 cases per 100,000 persons per year, and a concerning trend of late-stage diagnoses [4] - Breast cancer is the most common cancer among women in Egypt, with an age-standardized incidence rate of about 55.4 per 100,000 persons per year, and poorer mortality outcomes due to late-stage diagnosis [5] - Prostate cancer ranks as the fourth most common cancer in Egypt, with increasing incidence rates [6] Health Statistics - Approximately 13% of adults in Egypt are living with chronic kidney disease, which has been among the top five causes of death from 2009 to 2019 [8] - H. pylori infection prevalence in Egypt ranges from 50% to 70%, affecting a significant portion of the population [8] Strategic Impact - The authorization supports national public health efforts to improve early disease detection, enhance health outcomes, and reduce long-term healthcare costs [9][10] - Biomerica's expansion in the Middle East and North Africa (MENA) region is reinforced by this authorization, aligning with global preventive care trends [11]

Core Insights - Myriad Genetics has expanded its MyRisk Hereditary Cancer Test to include 100% of genes strongly recommended by national oncology guidelines, enhancing its position in molecular diagnostic testing [1][2][3] Group 1: Test Expansion and Clinical Relevance - The updated MyRisk panel now includes 63 selected genes associated with over 11 cancer types, reflecting the company's commitment to evolving clinical needs [2] - The MyRisk Test is designed to provide clinical value throughout the cancer care continuum, aiding in treatment decisions, surveillance planning, and family risk assessment [3] Group 2: Company Commitment and Expertise - Myriad Genetics emphasizes its expertise in interpreting DNA variants, which significantly impacts patient care, prioritizing genes that influence treatment decisions [3] - The company aims to provide high clinical utility insights to clinicians and genetic counselors, ensuring that the MyRisk Test remains relevant as guidelines evolve [3] Group 3: Accessibility and Integration - Clinicians can conveniently order and review MyRisk Test results through various platforms, including paper forms, the Myriad patient portal, and electronic medical record systems like EPIC and OncoEMR [3]

Group 1: Market Sentiment - Wall Street shows strong bullish sentiment on the stocks discussed, with price targets indicating significant upside potential [1] - Analysts are generally reluctant to issue sell ratings due to potential conflicts of interest with their firms [1] Group 2: 8x8 (EGHT) - 8x8 has a consensus price target of $2.50, suggesting a 27.7% implied return [3] - The stock is currently trading at $1.96 per share, equating to 0.4x forward price-to-sales [5] - Concerns include stagnant billings, flat projected sales, and increased competition requiring higher marketing expenditures [10] Group 3: Malibu Boats (MBUU) - Malibu Boats has a consensus price target of $36.07, indicating a 34% implied return [6] - The stock trades at $26.92 per share, with a forward P/E ratio of 21.3x [8] - Issues include low demand reflected in underwhelming boat sales, declining earnings per share by 14.9% annually, and diminishing returns on capital [11] Group 4: Neogen (NEOG) - Neogen has a consensus price target of $8.17, suggesting a 34.1% implied return [9] - The company operates in the food safety and animal health sectors, developing diagnostic tests for dangerous substances [9]

Core Insights - Myriad Genetics, Inc. announced the presentation of 11 new research studies focused on advancements in oncology and reproductive genetic testing at the NSGC 44 Annual Conference [1][2] - The studies will feature products such as MyRisk Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel Prenatal Screen, and Foresight Carrier Screen [1] Company Commitment - The company emphasizes its commitment to advancing scientific research to improve patient outcomes and provide innovative, data-driven insights for personalized patient care [2] - Myriad Genetics aims to enhance accessibility to genetic testing through collaboration with the genetic counseling community [2] Conference Participation - Myriad Genetics will showcase its latest innovations and support services at booth 317 and through poster presentations during the conference [2] - The presentation schedule includes sessions on November 7 and November 8, 2025 [3] Research Highlights - Key research topics include RNA analysis for interpreting Variants of Uncertain Significance (VUS), fetal fraction amplification for cfDNA screening, and prenatal cell-free DNA screening for maternal colorectal cancer [6] - Additional studies focus on the evolution of genetic screening reports, the spectrum of germline hereditary cancer mutations, and professional development for genetic counselors [6] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, dedicated to improving health and well-being through molecular tests that assess disease risk and guide treatment decisions [4]

Q3 2025 Performance Highlights - Total revenue increased by 13.1% to $2.82 billion[1, 5, 14] - Adjusted diluted EPS reached $2.60 per share[1, 14] - Operating income increased 16.8% to $386 million[14] - Adjusted operating income increased 18.9% to $458 million[14] - Net income attributable to Quest Diagnostics increased 8.5% to $245 million[14] Growth Drivers - Organic revenue growth was 6.8%[5] - Total requisition volume increased by 12.5%[14] - Organic requisition volume increased by 3.9%[14] Strategic Initiatives - Established a lab services joint venture with Corewell Health, expecting Co-Lab Solutions annual revenues to reach approximately $1 billion[6] - Announced Epic as the technology partner for Project Nova[7] 2025 Full Year Guidance - Updated net revenue guidance to $10.96 billion - $11.00 billion, representing an increase of 11.0% - 11.4%[16] - Updated adjusted diluted EPS guidance to $9.76 - $9.84[16]

Core Insights - Myriad Genetics has added two genes, F8 and FXN, to its Foresight Carrier Screen Universal Plus Panel, enhancing its compliance with the American College of Medical Genetics and Genomics recommendations [1][4]. Gene-Specific Information - Variants in the F8 gene are associated with hemophilia A, a hereditary bleeding disorder that can lead to prolonged bleeding [2]. - The FXN gene is linked to Friedreich's ataxia, a rare neurodegenerative disease that causes motor weakness and sensory loss [3]. Product Features and Impact - The Foresight Carrier Screen is designed to provide vital genetic insights for informed family planning, with a detection rate of one in 22 couples for serious inherited conditions [6]. - The Foresight Carrier Screen has been validated through over 20 peer-reviewed publications and is the only expanded carrier screening test with published analytical validation in the US [5]. Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on improving patient care and reducing healthcare costs through molecular insights [7].

Core Viewpoint - QuidelOrtho Corporation is expanding its QUICKVUE portfolio with the introduction of the QUICKVUE Influenza + SARS Test, aimed at enhancing point-of-care diagnostic testing capabilities for respiratory illnesses [1][3]. Product Features and Benefits - The QUICKVUE Influenza + SARS Test allows for rapid, simultaneous detection of influenza A, influenza B, and SARS-CoV-2 antigens from a single patient sample, providing results in as fast as 10 minutes [2][5]. - This test is designed for use in various healthcare settings, including physician office laboratories, urgent care centers, emergency departments, and pharmacies, facilitating timely treatment decisions and improved patient outcomes [2][3]. - The test is a CLIA-waived, 510(k)–cleared immunoassay, emphasizing its reliability and efficiency in differentiating between COVID-19 and seasonal flu infections [1][3]. Market Position and Strategy - The launch of the QUICKVUE Influenza + SARS Test reinforces QuidelOrtho's leadership in point-of-care respiratory testing and expands its portfolio of respiratory solutions [3][4]. - The company aims to provide healthcare professionals with cost-effective solutions that streamline clinical decisions and manage seasonal surges in respiratory infections [3][4]. - QuidelOrtho's commitment to innovation is evident in its continuous development of diagnostic solutions that improve patient outcomes across various healthcare settings [4].

Core Insights - Telo Genomics presented a new methodology for minimal residual disease (MRD) assessment at the 22nd International Myeloma Society Annual Meeting, highlighting its innovative approach in the field of multiple myeloma diagnostics [1][2][4] Company Overview - Telo Genomics is a biotech company specializing in diagnostic and prognostic tests through telomere analysis, with a focus on liquid biopsies and related technologies in oncology and neurological diseases [5] - The company aims to improve patient care by developing accurate products that cater to the needs of pathologists, clinicians, academic researchers, and drug developers [5] MRD Methodology - The presented abstract details a new workflow for MRD evaluation that integrates the enumeration and immunophenotyping of individual Multiple Myeloma Circulating Tumor Cells (CTCs) with the TeloView® 3D telomere profiling platform [3] - This method utilizes peripheral blood for CTC evaluation, offering a less invasive biomarker for continuous patient monitoring, and provides actionable insights on disease progression risk [3] Market Context - The MRD testing industry is expected to experience significant growth, with the global market projected to reach USD 4.1 billion by 2032 [6] - The FDA's acceptance of MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies indicates a shift towards more personalized healthcare and faster drug approvals [6] Multiple Myeloma Insights - Multiple Myeloma is the second most common blood cancer, with approximately 35,000 new cases annually in the US and around 180,000 patients undergoing treatment at any given time [8] - The introduction of next-generation therapies has improved the median survival rate to over 5 years, yet the disease remains incurable [8] - Identifying patients at risk of rapid progression to symptomatic MM is a critical clinical need, as treatment costs can reach up to $150,000 per year per patient [8]

Core Viewpoint - QuidelOrtho Corporation (NASDAQ:QDEL) is recognized as one of the best small-cap stocks to buy, with RBC Capital raising its price target from $60 to $62 while maintaining a Buy rating [1][3]. Financial Performance and Strategy - QuidelOrtho has successfully completed a series of transactions to refinance its debt structure, extending debt maturities and reducing required amortization payments, which enhances financial flexibility [2][3]. - The company prioritizes reducing total debt and net debt leverage, improving debt covenant terms, and enhancing cash flow to support future growth [3]. Market Growth and Opportunities - The company has experienced significant growth in international markets during Q2 FY2025, particularly in Latin America, Japan, Asia Pacific, and EMEA regions [4]. - QuidelOrtho is focusing on its molecular strategy, including the acquisition of LEX Diagnostics, which is expected to enhance its growth potential [4]. Analyst Insights - As of September 5, the average price target for QuidelOrtho is $37.50, indicating an upside potential of approximately 30.75% from current levels [5]. - QuidelOrtho operates in various segments, including Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics [5].